Base de dados : MEDLINE
Pesquisa : D09.067.342.300 [Categoria DeCS]
Referências encontradas : 1429 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 143 ir para página                         

  1 / 1429 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29059687
[Au] Autor:Conlin PR; Colburn J; Aron D; Pries RM; Tschanz MP; Pogach L
[Ad] Endereço:From VA Boston Healthcare System, West Roxbury, Massachusetts; San Antonio Military Medical Center, Fort Sam Houston, Texas; Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio; VHA National Center for Health Promotion and Disease Prevention, Durham, North Carolina; San Diego Internal Medicine
[Ti] Título:Synopsis of the 2017 U.S. Department of Veterans Affairs/U.S. Department of Defense Clinical Practice Guideline: Management of Type 2 Diabetes Mellitus.
[So] Source:Ann Intern Med;167(9):655-663, 2017 Nov 07.
[Is] ISSN:1539-3704
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Description: In April 2017, the U.S. Department of Veterans Affairs (VA) and the U.S. Department of Defense (DoD) approved a joint clinical practice guideline for the management of type 2 diabetes mellitus. Methods: The VA/DoD Evidence-Based Practice Work Group convened a joint VA/DoD guideline development effort that included a multidisciplinary panel of practicing clinician stakeholders and conformed to the Institute of Medicine's tenets for trustworthy clinical practice guidelines. The guideline panel developed key questions in collaboration with the ECRI Institute, which systematically searched and evaluated the literature through June 2016, developed an algorithm, and rated recommendations by using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) system. Recommendations: This synopsis summarizes key features of the guideline in 7 areas: patient-centered care and shared decision making, glycemic biomarkers, hemoglobin A1c target ranges, individualized treatment plans, outpatient pharmacologic treatment, glucose targets for critically ill patients, and treatment of hospitalized patients.
[Mh] Termos MeSH primário: Diabetes Mellitus Tipo 2/terapia
[Mh] Termos MeSH secundário: Biomarcadores/sangue
Glicemia/metabolismo
Tomada de Decisão Clínica
Tomada de Decisões
Diabetes Mellitus Tipo 2/sangue
Diabetes Mellitus Tipo 2/complicações
Angiopatias Diabéticas/prevenção & controle
Frutosamina/sangue
Hemoglobina A Glicada/metabolismo
Seres Humanos
Hipoglicemiantes/uso terapêutico
Expectativa de Vida
Preferência do Paciente
Assistência Centrada no Paciente
[Pt] Tipo de publicação:JOURNAL ARTICLE; PRACTICE GUIDELINE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Blood Glucose); 0 (Glycated Hemoglobin A); 0 (Hypoglycemic Agents); 4429-04-3 (Fructosamine)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171024
[St] Status:MEDLINE
[do] DOI:10.7326/M17-1362


  2 / 1429 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28605777
[Au] Autor:Bergenstal RM; Gal RL; Connor CG; Gubitosi-Klug R; Kruger D; Olson BA; Willi SM; Aleppo G; Weinstock RS; Wood J; Rickels M; DiMeglio LA; Bethin KE; Marcovina S; Tassopoulos A; Lee S; Massaro E; Bzdick S; Ichihara B; Markmann E; McGuigan P; Woerner S; Ecker M; Beck RW; T1D Exchange Racial Differences Study Group
[Ad] Endereço:From International Diabetes Center Park Nicollet, Minneapolis, Minnesota; Jaeb Center for Health Research, Tampa, Florida; University Hospitals of Cleveland, Cleveland, Ohio; Henry Ford Health System, Detroit, Michigan; Children's Hospital of Philadelphia and Perelman School of Medicine and Rodebaug
[Ti] Título:Racial Differences in the Relationship of Glucose Concentrations and Hemoglobin A1c Levels.
[So] Source:Ann Intern Med;167(2):95-102, 2017 Jul 18.
[Is] ISSN:1539-3704
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Background: Debate exists as to whether the higher hemoglobin A1c (HbA1c) levels observed in black persons than in white persons are due to worse glycemic control or racial differences in the glycation of hemoglobin. Objective: To determine whether a racial difference exists in the relationship of mean glucose and HbA1c. Design: Prospective, 12-week observational study. Setting: 10 diabetes centers in the United States. Participants: 104 black persons and 104 white persons aged 8 years or older who had had type 1 diabetes for at least 2 years and had an HbA1c level of 6.0% to 12.0%. Measurements: Mean glucose concentration, measured by using continuous glucose monitoring and compared by race with HbA1c, glycated albumin, and fructosamine values. Results: The mean HbA1c level was 9.1% in black persons and 8.3% in white persons. For a given HbA1c level, the mean glucose concentration was significantly lower in black persons than in white persons (P = 0.013), which was reflected in mean HbA1c values in black persons being 0.4 percentage points (95% CI, 0.2 to 0.6 percentage points) higher than those in white persons for a given mean glucose concentration. In contrast, no significant racial differences were found in the relationship of glycated albumin and fructosamine levels with the mean glucose concentration (P > 0.20 for both comparisons). Limitation: There were too few participants with HbA1c levels less than 6.5% to generalize the results to such individuals. Conclusion: On average, HbA1c levels overestimate the mean glucose concentration in black persons compared with white persons, possibly owing to racial differences in the glycation of hemoglobin. However, because race only partially explains the observed HbA1c differences between black persons and white persons, future research should focus on identifying and modifying barriers impeding improved glycemic control in black persons with diabetes. Primary Funding Source: Helmsley Charitable Trust.
[Mh] Termos MeSH primário: Grupo com Ancestrais do Continente Africano
Glicemia/metabolismo
Diabetes Mellitus Tipo 1/sangue
Diabetes Mellitus Tipo 1/etnologia
Grupo com Ancestrais do Continente Europeu
Hemoglobina A Glicada/metabolismo
[Mh] Termos MeSH secundário: Adolescente
Adulto
Automonitorização da Glicemia
Criança
Feminino
Frutosamina/sangue
Seres Humanos
Masculino
Meia-Idade
Estudos Prospectivos
Albumina Sérica/metabolismo
Estados Unidos
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Glycated Hemoglobin A); 0 (Serum Albumin); 0 (glycosylated serum albumin); 4429-04-3 (Fructosamine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170613
[St] Status:MEDLINE
[do] DOI:10.7326/M16-2596


  3 / 1429 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28437840
[Au] Autor:Mariosa D; Hammar N; Malmström H; Ingre C; Jungner I; Ye W; Fang F; Walldius G
[Ad] Endereço:Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
[Ti] Título:Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20-year follow-up of the Swedish AMORIS cohort.
[So] Source:Ann Neurol;81(5):718-728, 2017 May.
[Is] ISSN:1531-8249
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To assess the associations of blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms with the future risk of amyotrophic lateral sclerosis (ALS). METHODS: In the Apolipoprotein-related MOrtality RISk study, we enrolled 636,132 men and women during 1985-1996 in Stockholm, Sweden, with measurements of serum glucose, total cholesterol, triglycerides, apolipoprotein B (apoB), and apolipoprotein A-I (apoA-I). Serum low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were either directly measured or calculated from total cholesterol, triglycerides, and apoA-I. The cohort was followed until the end of 2011. We used Cox models and mixed-effects models to, first, estimate the associations between these biomarkers and ALS incidence and, second, to assess the changes of these biomarkers during the 20 years before ALS diagnosis. RESULTS: One-unit increase of LDL-C (hazard ratio [HR] = 1.14; 95% confidence interval [CI] = 1.02-1.27), apoB (HR = 1.68; 95% CI = 1.17-2.42), and apoB/apoA-I ratio (HR = 1.90; 95% CI = 1.29-2.78) was associated with a higher incidence of ALS. High glucose level (≥6.11mmol/L) was associated with a lower incidence (HR = 0.62; 95% CI = 0.42-0.93), whereas high LDL-C/HDL-C (≥3.50; HR = 1.50; 95% CI = 1.15-1.96) and high apoB/apoA-I (≥0.90 for men, ≥0.8 for women; HR = 1.41; 95% CI = 1.04-1.90) ratios were associated with a higher incidence. During the 10 years before diagnosis, ALS patients had increasing levels of LDL-C, HDL-C, apoB, and apoA-I, whereas gradually decreasing levels of LDL-C/HDL-C and apoB/apoA-I ratios. INTERPRETATION: Alterations in the carbohydrate, lipid, and apolipoprotein metabolisms are associated with ALS risk and may serve as prodromal symptoms decades before ALS diagnosis. The imbalance between apoB and apoA-I as well as between LDL-C and HDL-C may be an etiological mechanism for ALS and needs to be further studied. Ann Neurol 2017;81:718-728.
[Mh] Termos MeSH primário: Esclerose Amiotrófica Lateral/sangue
Apolipoproteína A-I/sangue
Apolipoproteínas B/sangue
Glicemia/metabolismo
HDL-Colesterol/sangue
LDL-Colesterol/sangue
Frutosamina/sangue
Sistema de Registros/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Esclerose Amiotrófica Lateral/epidemiologia
Biomarcadores/sangue
Estudos de Casos e Controles
Feminino
Seguimentos
Seres Humanos
Incidência
Masculino
Meia-Idade
Risco
Suécia/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Apolipoprotein A-I); 0 (Apolipoproteins B); 0 (Biomarkers); 0 (Blood Glucose); 0 (Cholesterol, HDL); 0 (Cholesterol, LDL); 4429-04-3 (Fructosamine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170719
[Lr] Data última revisão:
170719
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170425
[St] Status:MEDLINE
[do] DOI:10.1002/ana.24936


  4 / 1429 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28182820
[Au] Autor:Kjær TN; Ornstrup MJ; Poulsen MM; Stødkilde-Jørgensen H; Jessen N; Jørgensen JOL; Richelsen B; Pedersen SB
[Ad] Endereço:Department of Endocrinology, Aarhus University Hospital, 8000 Aarhus, Denmark.
[Ti] Título:No Beneficial Effects of Resveratrol on the Metabolic Syndrome: A Randomized Placebo-Controlled Clinical Trial.
[So] Source:J Clin Endocrinol Metab;102(5):1642-1651, 2017 May 01.
[Is] ISSN:1945-7197
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Context: Low-grade inflammation is associated with obesity and the metabolic syndrome (MetS). Preclinical evidence suggests that resveratrol (RSV) has beneficial metabolic and anti-inflammatory effects that could have therapeutic implications. Objective: To investigate effects of long-term RSV treatment on inflammation and MetS. Setting and Design: A randomized, placebo-controlled, double-blind, parallel group clinical trial conducted at Aarhus University Hospital. Participants: Middle-aged community-dwelling men (N = 74) with MetS, 66 of whom completed all visits (mean ± standard error of the mean): age, 49.5 ± 0.796 years; body mass index, 33.8 ± 0.44 kg/m2; waist circumference, 115 ± 1.14 cm. Intervention: Daily oral supplementation with 1000 mg RSV (RSVhigh), 150 mg RSV, or placebo for 16 weeks. Main outcome measures: Plasma levels of high-sensitivity C-reactive protein (hs-CRP), circulating lipids, and inflammatory markers in circulation and adipose/muscle tissue biopsy specimens; glucose metabolism; and body composition including visceral fat and ectopic fat deposition. Results: RSV treatment did not lower circulating levels of hs-CRP, interleukin 6, or soluble urokinase plasminogen activator receptor in plasma, and inflammatory gene expression in adipose and muscle tissues also remained unchanged. RSV treatment had no effect on blood pressure, body composition, and lipid deposition in the liver or striated muscle. RSV treatment had no beneficial effect on glucose or lipid metabolism. RSVhigh treatment significantly increased total cholesterol (P < 0.002), low-density lipoprotein (LDL) cholesterol (P < 0.006), and fructosamine (P < 0.013) levels compared with placebo. Conclusion: RSV treatment did not improve inflammatory status, glucose homeostasis, blood pressure, or hepatic lipid content in middle-aged men with MetS. On the contrary, RSVhigh significantly increased total cholesterol, LDL cholesterol, and fructosamine levels compared with placebo.
[Mh] Termos MeSH primário: Antioxidantes/uso terapêutico
Síndrome Metabólica/tratamento farmacológico
Estilbenos/uso terapêutico
[Mh] Termos MeSH secundário: Absorciometria de Fóton
Tecido Adiposo/imunologia
Tecido Adiposo/metabolismo
Glicemia/metabolismo
Pressão Sanguínea
Western Blotting
Composição Corporal
Proteína C-Reativa/imunologia
Colesterol/metabolismo
HDL-Colesterol/metabolismo
LDL-Colesterol/metabolismo
Método Duplo-Cego
Frutosamina/metabolismo
Seres Humanos
Insulina/metabolismo
Resistência à Insulina
Interleucina-6/imunologia
Gordura Intra-Abdominal/diagnóstico por imagem
Gordura Intra-Abdominal/metabolismo
Leptina/metabolismo
Fígado/diagnóstico por imagem
Fígado/metabolismo
Imagem por Ressonância Magnética
Espectroscopia de Ressonância Magnética
Masculino
Síndrome Metabólica/imunologia
Síndrome Metabólica/metabolismo
Meia-Idade
Músculo Esquelético/diagnóstico por imagem
Músculo Esquelético/imunologia
Músculo Esquelético/metabolismo
Músculo Quadríceps/imunologia
Músculo Quadríceps/metabolismo
Reação em Cadeia da Polimerase em Tempo Real
Receptores de Ativador de Plasminogênio Tipo Uroquinase/metabolismo
Triglicerídeos/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Antioxidants); 0 (Blood Glucose); 0 (Cholesterol, HDL); 0 (Cholesterol, LDL); 0 (IL6 protein, human); 0 (Insulin); 0 (Interleukin-6); 0 (Leptin); 0 (Receptors, Urokinase Plasminogen Activator); 0 (Stilbenes); 0 (Triglycerides); 4429-04-3 (Fructosamine); 9007-41-4 (C-Reactive Protein); 97C5T2UQ7J (Cholesterol); Q369O8926L (resveratrol)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170210
[St] Status:MEDLINE
[do] DOI:10.1210/jc.2016-2160


  5 / 1429 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28121184
[Au] Autor:Ruffino JS; Songsorn P; Haggett M; Edmonds D; Robinson AM; Thompson D; Vollaard NB
[Ad] Endereço:a Department for Health, University of Bath, Bath, BA2 7AY, UK.
[Ti] Título:A comparison of the health benefits of reduced-exertion high-intensity interval training (REHIT) and moderate-intensity walking in type 2 diabetes patients.
[So] Source:Appl Physiol Nutr Metab;42(2):202-208, 2017 Feb.
[Is] ISSN:1715-5320
[Cp] País de publicação:Canada
[La] Idioma:eng
[Ab] Resumo:Reduced-exertion high-intensity interval training (REHIT) is a genuinely time-efficient intervention that can improve aerobic capacity and insulin sensitivity in sedentary individuals. The present study compared the effects of REHIT and moderate-intensity walking on health markers in patients with type 2 diabetes (T2D) in a counter-balanced crossover study. Sixteen men with T2D (mean ± SD age: 55 ± 5 years, body mass index: 30.6 ± 2.8 kg·m , maximal aerobic capacity: 27 ± 4 mL·kg ·min ) completed 8 weeks of REHIT (three 10-min low-intensity cycling sessions/week with two "all-out" 10-20-s sprints) and 8 weeks of moderate-intensity walking (five 30-min sessions/week at an intensity corresponding to 40%-55% of heart-rate reserve), with a 2-month wash-out period between interventions. Before and after each intervention, participants underwent an incremental fitness test, an oral glucose tolerance test (OGTT), a whole-body dual-energy X-ray absorptiometry scan, and continuous glucose monitoring. REHIT was associated with a significantly larger increase in maximal aerobic capacity compared with walking (7% vs. 1%; time × intervention interaction effect: p < 0.05). Both REHIT and walking decreased resting mean arterial pressure (-4%; main effect of time: p < 0.05) and plasma fructosamine (-5%; main effect of time: p < 0.05). Neither intervention significantly improved OGTT-derived measures of insulin sensitivity, glycaemic control measured using continuous glucose monitors, blood lipid profile, or body composition. We conclude that REHIT is superior to a 5-fold larger volume of moderate-intensity walking in improving aerobic fitness, but similar to walking REHIT is not an effective intervention for improving insulin sensitivity or glycaemic control in T2D patients in the short term.
[Mh] Termos MeSH primário: Diabetes Mellitus Tipo 2/terapia
Exercício
Treinamento Intervalado de Alta Intensidade
Obesidade/terapia
Sobrepeso/terapia
Esforço Físico
[Mh] Termos MeSH secundário: Adulto
Biomarcadores/sangue
Índice de Massa Corporal
Estudos Cross-Over
Diabetes Mellitus Tipo 2/sangue
Diabetes Mellitus Tipo 2/complicações
Diabetes Mellitus Tipo 2/metabolismo
Inglaterra
Frutosamina/sangue
Frequência Cardíaca
Seres Humanos
Hiperglicemia/prevenção & controle
Resistência à Insulina
Masculino
Meia-Idade
Obesidade/sangue
Obesidade/complicações
Obesidade/metabolismo
Sobrepeso/sangue
Sobrepeso/complicações
Sobrepeso/metabolismo
Pacientes Desistentes do Tratamento
Caminhada
[Pt] Tipo de publicação:CLINICAL TRIAL; COMPARATIVE STUDY; JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Biomarkers); 4429-04-3 (Fructosamine)
[Em] Mês de entrada:1702
[Cu] Atualização por classe:170203
[Lr] Data última revisão:
170203
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170126
[St] Status:MEDLINE
[do] DOI:10.1139/apnm-2016-0497


  6 / 1429 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28092845
[Au] Autor:Hosni AA; Abdel-Moneim AA; Abdel-Reheim ES; Mohamed SM; Helmy H
[Ad] Endereço:Molecular Physiology Division, Zoology Department, Faculty of Science, Beni-Suef University, 62511 Beni-Suef, Egypt.
[Ti] Título:Cinnamaldehyde potentially attenuates gestational hyperglycemia in rats through modulation of PPARγ, proinflammatory cytokines and oxidative stress.
[So] Source:Biomed Pharmacother;88:52-60, 2017 Apr.
[Is] ISSN:1950-6007
[Cp] País de publicação:France
[La] Idioma:eng
[Ab] Resumo:Cinnamon has a history of use for medicinal purposes and its major benefits have been linked to cinnamaldehyde. The present study aimed to investigate the hypoglycemic action of cinnamaldehyde against fatty-sucrosed diet/streptozotocin (FSD/STZ)-rat model of gestational diabetes. Female albino rats were divided into three groups. Group I fed with normal diet (ND) while group II and III were fed with FSD for eight weeks (five weeks pre-gestational and three weeks gestational). Rats of group III were administered with a daily oral dose of 20mg/kg cinnamaldehyde one week before mating onward. At the 7th day of gestation, FSD-fed rats were injected intraperitoneally with STZ (25mg/kg b.wt.) to induce gestational diabetes. Pre-mating treatment of cinnamaldehyde controls hyperphagia and glucose intolerance during the gestational period than in diabetic rats. It also reduced levels of fructosamine, total cholesterols, triglycerides, leptin, tumor necrosis factor-alpha (TNF-α), malondialdehyde (MDA) and nitric oxide (NO), while it significantly increased levels of high-density lipoprotein (HDL)-cholesterol, adiponectin, liver glycogen, reduced glutathione (GSH) and catalase activity at term pregnancy. In addition, cinnamaldehyde administration up-regulated the mRNA expression of peroxisome proliferated activated receptor-gamma (PPARγ) and also ameliorated the number of viable fetuses, implantation loss sites, fetal glucose and insulin levels. In conclusion, cinnamaldehyde has safe hypoglycemic action on gestational diabetes by potentiating insulin secretion and sensitivity through activating the antioxidant defense system, suppressing pro-inflammatory cytokines production, upregulating PPARγ gene expression and alleviating the reproductive performance.
[Mh] Termos MeSH primário: Acroleína/análogos & derivados
Citocinas/metabolismo
Diabetes Gestacional/tratamento farmacológico
Diabetes Gestacional/patologia
Hiperglicemia/tratamento farmacológico
Mediadores da Inflamação/metabolismo
Estresse Oxidativo
PPAR gama/metabolismo
[Mh] Termos MeSH secundário: Acroleína/farmacologia
Acroleína/uso terapêutico
Tecido Adiposo/metabolismo
Animais
Antioxidantes/metabolismo
Biomarcadores/metabolismo
Glicemia/metabolismo
Peso Corporal/efeitos dos fármacos
Colesterol/sangue
Diabetes Gestacional/sangue
Diabetes Gestacional/genética
Comportamento Alimentar/efeitos dos fármacos
Feminino
Feto/metabolismo
Frutosamina/sangue
Teste de Tolerância a Glucose
Glicogênio/metabolismo
Hiperglicemia/sangue
Hiperglicemia/genética
Hiperglicemia/patologia
Insulina/sangue
Leptina/sangue
Fígado/metabolismo
Estresse Oxidativo/efeitos dos fármacos
PPAR gama/genética
Gravidez
Resultado da Gravidez
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
Ratos
Triglicerídeos/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antioxidants); 0 (Biomarkers); 0 (Blood Glucose); 0 (Cytokines); 0 (Inflammation Mediators); 0 (Insulin); 0 (Leptin); 0 (PPAR gamma); 0 (RNA, Messenger); 0 (Triglycerides); 4429-04-3 (Fructosamine); 7864XYD3JJ (Acrolein); 9005-79-2 (Glycogen); 97C5T2UQ7J (Cholesterol); SR60A3XG0F (cinnamic aldehyde)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:170327
[Lr] Data última revisão:
170327
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170117
[St] Status:MEDLINE


  7 / 1429 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27608964
[Au] Autor:Tupe RS; Kemse NG; Khaire AA; Shaikh SA
[Ad] Endereço:a Biochemical Sciences Division, Rajiv Gandhi Institute of IT and Biotechnology , Bharati Vidyapeeth University , Pune , Maharashtra , India.
[Ti] Título:Attenuation of glycation-induced multiple protein modifications by Indian antidiabetic plant extracts.
[So] Source:Pharm Biol;55(1):68-75, 2017 Dec.
[Is] ISSN:1744-5116
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:CONTEXT: Protein glycation is the major contributing factor in the development of diabetic complications. The antiglycation potential of medicinal plants provides a promising opportunity as complementary interventions for complications. OBJECTIVE: To investigate the antiglycation potential of 19 medicinal plants extracts using albumin by estimating different indicators: (1) glycation (early and late), (2) albumin oxidation, and (3) amyloid aggregation. MATERIALS AND METHODS: The effect of aqueous plant extracts (1% w/v) on protein glycation was assessed by incubating albumin (10 mg/mL) with fructose (250 mM) for 4 days. Degree of protein glycation in the absence and presence of plant extracts was assessed by estimating fructosamine, advanced glycation end products (AGEs), carbonyls, free thiol group and ß-amyloid aggregation. RESULTS: Petroselinum crispum, Boerhavia diffusa, Terminalia chebula, Swertia chirayita and Glycyrrhiza glabra showed significant antiglycating activity. P. crispum and A. barbadensis inhibited the carbonyl stress and protected the thiol group from oxidative damage. There was significant correlation between protein thiols and amyloid inhibition (R = -.69, p < .001). CONCLUSION: P. crispum, B. diffusa and T. chebula had the most potent antiglycation activity. These plant exerted noticeable antiglycation activity at different glycation modifications of albumin. These findings are important for identifying plants with potential to combat diabetic complications.
[Mh] Termos MeSH primário: Peptídeos beta-Amiloides/metabolismo
Produtos Finais de Glicação Avançada/metabolismo
Hipoglicemiantes/farmacologia
Nyctaginaceae/química
Petroselinum/química
Extratos Vegetais/farmacologia
Processamento de Proteína Pós-Traducional/efeitos dos fármacos
Soroalbumina Bovina/metabolismo
Terminalia/química
[Mh] Termos MeSH secundário: Frutosamina/metabolismo
Frutose/metabolismo
Glicosilação
Hipoglicemiantes/isolamento & purificação
Índia
Oxirredução
Fitoterapia
Extratos Vegetais/isolamento & purificação
Plantas Medicinais
Agregação Patológica de Proteínas
Carbonilação Proteica/efeitos dos fármacos
Compostos de Sulfidrila/metabolismo
Fatores de Tempo
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Amyloid beta-Peptides); 0 (Glycation End Products, Advanced); 0 (Hypoglycemic Agents); 0 (Plant Extracts); 0 (Sulfhydryl Compounds); 0 (advanced glycation end products-bovine serum albumin); 27432CM55Q (Serum Albumin, Bovine); 30237-26-4 (Fructose); 4429-04-3 (Fructosamine)
[Em] Mês de entrada:1703
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160910
[St] Status:MEDLINE


  8 / 1429 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:27598983
[Au] Autor:Gomes JMG; Fabrini SP; Alfenas RCG
[Ad] Endereço:Instituto Federal de Educação, Ciência e Tecnologia do Sudeste de Minas Gerais, Campus Barbacena, Barbacena, MG, Brasil.
[Ti] Título:Low glycemic index diet reduces body fat and attenuates inflammatory and metabolic responses in patients with type 2 diabetes.
[So] Source:Arch Endocrinol Metab;61(2):137-144, 2017 Mar-Apr.
[Is] ISSN:2359-4292
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:Objective: The aim of this study was to verify the effects of glycemic index (GI) on body composition, and on inflammatory and metabolic markers concentrations in patients with type 2 diabetes. Subjects and methods: In this randomized controlled parallel trial, twenty subjects (aged 42.4 ± 5.1 years, BMI 29.2 ± 4.8 kg.m-2) were allocated to low GI (LGI) (n = 10) or high GI (HGI) (n = 10) groups. Body composition, inflammatory and metabolic markers were assessed at baseline and after 30 days of intervention. Food intake was monitored during the study using three-day food records completed on two non-consecutive weekdays and on a weekend day. Results: Body fat reduced after the LGI intervention compared with baseline (P = 0.043) and with the HGI group (P = 0.036). Serum fructosamine concentration (P = 0.031) and TNF-α mRNA expression (P = 0.05) increased in the HGI group. Serum non-esterified fatty acids were greater in the HGI than in the LGI group (P = 0.032). IL-6 mRNA expression tended to decrease after the consumption of the LGI diet compared to baseline (P = 0.06). Conclusion: The LGI diet reduced body fat and prevented the negative metabolic and inflammatory responses induced by the HGI diet.
[Mh] Termos MeSH primário: Tecido Adiposo/metabolismo
Diabetes Mellitus Tipo 2/dietoterapia
Diabetes Mellitus Tipo 2/metabolismo
Índice Glicêmico/fisiologia
[Mh] Termos MeSH secundário: Adulto
Antropometria
Glicemia/metabolismo
Composição Corporal
Fibras na Dieta/análise
Ingestão de Alimentos/fisiologia
Feminino
Frutosamina/sangue
Seres Humanos
Inflamação/metabolismo
Interleucina-6/sangue
Masculino
Meia-Idade
Reação em Cadeia da Polimerase em Tempo Real
Valores de Referência
Reprodutibilidade dos Testes
Estatísticas não Paramétricas
Fatores de Tempo
Resultado do Tratamento
Fator de Necrose Tumoral alfa/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Blood Glucose); 0 (Dietary Fiber); 0 (Interleukin-6); 0 (Tumor Necrosis Factor-alpha); 4429-04-3 (Fructosamine)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160907
[St] Status:MEDLINE


  9 / 1429 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27751668
[Au] Autor:Malmström H; Wändell PE; Holzmann MJ; Ärnlöv J; Jungner I; Hammar N; Walldius G; Carlsson AC
[Ad] Endereço:Unit of Epidemiology, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. Electronic address: hakan.malmstrom@ki.se.
[Ti] Título:Low fructosamine and mortality - A long term follow-up of 215,011 non-diabetic subjects in the Swedish AMORIS study.
[So] Source:Nutr Metab Cardiovasc Dis;26(12):1120-1128, 2016 Dec.
[Is] ISSN:1590-3729
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:BACKGROUND AND AIMS: Both high and low fasting glucose has been associated with an increased mortality among individuals without diabetes. This J-shaped association has also been shown for HbA1c in relation to all-cause mortality. High fructosamine is associated with increased mortality. In this study we aim to evaluate if low fructosamine is also associated with increased mortality in non-diabetic subjects. METHODS AND RESULTS: We included 215,011 subjects from the AMORIS cohort undergoing occupational health screening or primary care in Stockholm, Sweden. Cause specific mortality was obtained from the Swedish Cause-of-Death Register by record linkage. Hazard ratios for the lowest decile of fructosamine were estimated by Cox regression for all-cause (n = 41,388 deaths) and cause-specific mortality during 25 years of follow-up. We observed gradually increased mortality with lower fructosamine in a large segment of the population. In the lowest decile of fructosamine the sex, age, social class and calendar adjusted hazard ratio was 1.20 (95% CI; 1.18-1.27) compared to deciles 2-9. This increased mortality was attenuated after adjustment for six other biomarkers (HR = 1.11 (95% CI; 1.07-1.15)). Haptoglobin, an indicator of chronic inflammation, made the greatest difference in the point estimate. In sensitivity analyses we found an association between low fructosamine and smoking and adjustment for smoking further attenuated the association between low fructosamine and mortality. CONCLUSION: Low levels of fructosamine in individuals without diabetes were found to be associated with increased mortality. Smoking and chronic inflammation seem to at least partially explain this association but an independent contribution by low fructosamine cannot be excluded.
[Mh] Termos MeSH primário: Frutosamina/sangue
Inflamação/mortalidade
Fumar/mortalidade
[Mh] Termos MeSH secundário: Adulto
Biomarcadores/sangue
Glicemia/metabolismo
Causas de Morte
Regulação para Baixo
Feminino
Seguimentos
Seres Humanos
Inflamação/sangue
Inflamação/diagnóstico
Masculino
Meia-Idade
Modelos de Riscos Proporcionais
Sistema de Registros
Medição de Risco
Fatores de Risco
Fumar/efeitos adversos
Fumar/sangue
Suécia
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Blood Glucose); 4429-04-3 (Fructosamine)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170731
[Lr] Data última revisão:
170731
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161019
[St] Status:MEDLINE


  10 / 1429 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27485656
[Au] Autor:Girish TK; Prasada Rao UJ
[Ad] Endereço:Department of Biochemistry and Nutrition, CSIR-CFTRI, Mysore, 570 020, India.
[Ti] Título:Protein glycation and aggregation inhibitory potency of biomolecules from black gram milled by-product.
[So] Source:J Sci Food Agric;96(15):4973-4983, 2016 Dec.
[Is] ISSN:1097-0010
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Persistent hyperglycaemia causes increased advanced glycation end products (AGEs), which contribute to the pathogenesis of diabetic complication. Therefore, effect of black gram milled by-product (BGBP) extract on inhibition of AGE formation in a bovine serum albumin (BSA)/glucose system was investigated. RESULTS: BGBP extract had a total polyphenol content of 82 mg GAE g and flavonoid content of 46 mg CE g . Ferulic acid, protocatechuic acid, gallic acid, gentisic acid, isovitexin, vitexin and epicatechin were the major bioactives in the extract. BGBP extract exhibited an effective Fe chelating activity. Size exclusion-high-performance liquid chromatographic studies indicated that upon BSA-AGE formation the BSA monomer content was 38%; however, in the presence of BGBP extract at 50 and 100 µg levels, the monomer content increased and it was found to be 48% and 73%, respectively. BGBP extract at 50 and 100 µg levels decreased the protein carbonyl and fructosamine contents, and quenched the fluorescence intensity of glycated BSA in a dose-dependent manner. Further, fluorescence and transmission electron microscopic studies confirmed the decrease in formation of AGEs by BGBP extract. CONCLUSION: As BGBP extract inhibited the formation of AGEs, the extract can be used as a nutraceutical or it can be incorporated into food products to obtain functional foods. © 2016 Society of Chemical Industry.
[Mh] Termos MeSH primário: Produtos Finais de Glicação Avançada/antagonistas & inibidores
Extratos Vegetais/farmacologia
Vigna/química
[Mh] Termos MeSH secundário: Quelantes/química
Flavonoides/análise
Frutosamina/análise
Glucose/química
Produtos Finais de Glicação Avançada/química
Glicosilação/efeitos dos fármacos
Microscopia Eletrônica de Transmissão
Polifenóis/análise
Polifenóis/farmacologia
Agregados Proteicos/efeitos dos fármacos
Carbonilação Proteica
Soroalbumina Bovina/química
Espectrometria de Fluorescência
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Chelating Agents); 0 (Flavonoids); 0 (Glycation End Products, Advanced); 0 (Plant Extracts); 0 (Polyphenols); 0 (Protein Aggregates); 27432CM55Q (Serum Albumin, Bovine); 4429-04-3 (Fructosamine); IY9XDZ35W2 (Glucose)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:160804
[St] Status:MEDLINE
[do] DOI:10.1002/jsfa.7980



página 1 de 143 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde